Peptides in Oncology: Targeting, Imaging, and Delivery

Tumors create molecular targets

Some cancers overexpress receptors or enzymes that can be recognized by peptide ligands. That creates opportunities for imaging, targeted delivery, or selective activation.

Peptides can carry signals or payloads

A targeting peptide may be linked to a radionuclide, fluorophore, cytotoxic drug, nanoparticle, or nucleic acid. Linker chemistry and receptor internalization can be as important as binding affinity.

Penetration is not guaranteed

Solid tumors have abnormal vasculature, high interstitial pressure, heterogeneous receptors, and dense extracellular matrix. A small peptide may penetrate better than an antibody, but rapid clearance can reduce exposure.

Proliferative pathways demand caution

Peptides that affect IGF, angiogenesis, repair, or immune signaling can have context-dependent effects in cancer biology. Mechanistic claims should account for receptor expression and tumor heterogeneity.

Companion diagnostics can strengthen the strategy

Imaging the target before treatment can help determine whether a receptor is present and whether a peptide reaches the lesion.

This article is provided for scientific and educational purposes. It does not describe or recommend human or veterinary use. Research findings may be limited by study design, model selection, material identity, sample size, or lack of independent replication.